Refine
Year of publication
Document Type
- Article (170)
- Preprint (43)
- Report (2)
- Review (2)
- Conference Proceeding (1)
- Working Paper (1)
Has Fulltext
- yes (219)
Is part of the Bibliography
- no (219)
Keywords
- LHC (8)
- Breast cancer (4)
- breast cancer (4)
- ALICE (3)
- ALICE experiment (3)
- Depression (3)
- Hadron-Hadron Scattering (3)
- SARS-CoV-2 (3)
- pp collisions (3)
- Beauty production (2)
- Bipolar disorder (2)
- COVID-19 (2)
- Diagnostik (2)
- Früherkennung (2)
- Gene expression (2)
- Genetics (2)
- HNSCC (2)
- Heavy Ions (2)
- Heavy-ion collisions (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Richtlinie (2)
- Single electrons (2)
- Surgery (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 18-Hydroxycorticosteron (1)
- 18-OH corticosterone (1)
- 900 GeV (1)
- AChE (1)
- ALICE LHC (1)
- APP (1)
- Active middle ear implants (1)
- Adherencia terapéutica (1)
- Afghanistan (1)
- Allogeneic hematopoietic stem cell transplantation (1)
- Alzheimer (1)
- Amizon (1)
- Amyloid precursor protein (1)
- Anandamide (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antirheumatic agents (1)
- Arteria ophthalmica (1)
- Artificial Intelligence (1)
- Atoms (1)
- Auditory system (1)
- Azacitidine (1)
- Balance function (1)
- Behavior (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Blindness (1)
- Bone conduction devices (1)
- Bone metastases (1)
- Botanical Collections (1)
- Business strategy in drug development (1)
- C3M (1)
- C4M (1)
- CA1 (1)
- CCL2 (1)
- CRISPR/Cas (1)
- CVID (1)
- Calorimeters (1)
- Cell membranes (1)
- Charge correlations (1)
- Charged-particle density (1)
- Charm physics (1)
- Chemical dispersant (1)
- Child (1)
- Child abuse (1)
- Childhood abuse (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Clinical variation (1)
- Cognitive impairment (1)
- Compact astrophysical objects (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Complex posttraumatic stress disorder (1)
- Compression stocking (1)
- Consensus (1)
- Consensus statement (1)
- Conservation (1)
- Conservation biogeography (1)
- DBT (1)
- DBT-PTS (1)
- DBT-PTSD (1)
- DBTTSD (1)
- DLI (1)
- Dataset bias (1)
- Ddialectic behavioural therapy (1)
- Decitabine (1)
- Deep vein thrombosis (1)
- Dermatomyositis (1)
- Diagnosis (1)
- Diagnostic markers (1)
- Dialectical behavioural therapy (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Digitization (1)
- Drug therapy (1)
- Dtherapeutic adherencetreatment integrity (1)
- EROD (1)
- Elderly (1)
- Embryo toxicity (1)
- Endocrinology (1)
- Epilepsy (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Excitability (1)
- Exilliteratur (1)
- Exilschriftsteller (1)
- Exilverlag (1)
- Exosomes (1)
- Extended donor criteria (1)
- FAV00A (1)
- FDG-PET/CT (1)
- FDM (1)
- Femtoscopy (1)
- Filler (1)
- Forschungsdatenmanagement (1)
- Frailty (1)
- Freiligrath, Ferdinand (1)
- Galaxies and clusters (1)
- General practitioners (1)
- Genetic wildlife monitoring (1)
- Genome editing (1)
- Genome-wide association studies (1)
- German PID-NET registry (1)
- Glabella (1)
- Global positioning system (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HDAC4 (1)
- HER2-positive (1)
- HPV-positive OPSCC (1)
- Hadron production (1)
- Hair sampling (1)
- Head and neck cancer (1)
- Head neck cancer (1)
- Health policy (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heinzen, Karl (1)
- Herbaria (1)
- High-energy astrophysics (1)
- Human behaviour (1)
- Hypertension (1)
- Hypomethylating agents (1)
- IN-VIVO (1)
- IS (1)
- IgG substitution therapy (1)
- Immunology (1)
- Immunotherapy (1)
- In situ burning (1)
- Inclusive spectra (1)
- Induction therapy (1)
- Inflammation (1)
- Integridad del tratamiento (1)
- Intensity interferometry (1)
- Intravenous injections (1)
- Ions (1)
- Irak (1)
- Islamischer Staat (1)
- Jets (1)
- Kidney diseases (1)
- Knockout (1)
- LOCKED NUCLEIC-ACID (1)
- Landesinitiative (1)
- Landesinitiative für Forschungsdatenmanagement (1)
- Large Hadron Collider (1)
- Lee-type (1)
- Library screening (1)
- Literarisches Institut (Herisau) (1)
- Luciferase (1)
- Lure sticks (1)
- Lymphoid Neoplasia (1)
- MAMMALIAN-CELLS (1)
- MODIFIED OLIGONUCLEOTIDES (1)
- Marker genes (1)
- Mental health and psychiatry (1)
- MicroRNAs (1)
- Microarray (1)
- Microglial cells (1)
- Mid-rapidity (1)
- Mixed hearing loss (1)
- Monte Carlo (1)
- Mott metal-insulator transition (1)
- Mouse models (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- NCoR1 (1)
- NFDI (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- Nationale Forschungsdateninfrastruktur (1)
- Nebennierenrinden-Adenom (1)
- Nebennierenrinden-Hyperplasie (1)
- Neoadjuvant therapy (1)
- Neuronal morphology (1)
- Neurons (1)
- Neuroscience (1)
- Noninvasive genetic sampling (1)
- Nuclear modification factor (1)
- Occlusion (1)
- Oldest-old (1)
- Oncology (1)
- Ophthalmoplegia (1)
- Optogenetics (1)
- Organ allocation (1)
- PASSENGER-STRAND (1)
- PID prevalence (1)
- PTS (1)
- PTSD (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Parkinson disease (1)
- Pathological complete response (1)
- Patterns of care (1)
- Pb–Pb (1)
- Performance of High Energy Physics Detectors (1)
- Perturbative methods (1)
- Phosphorylation (1)
- Pooling (1)
- Population-based screening (1)
- Post-traumatic stress disorder (1)
- Posttraumatic stress disorder (1)
- Proton–proton (1)
- Psychological and psychosocial issues (1)
- Pulmonary embolism (1)
- Quality of life (1)
- RDM (1)
- RNA polymerase (1)
- RT-qPCR (1)
- Radiotherapy (1)
- Randomised controlled trial (1)
- Recall rate (1)
- Red blood cell transfusion (1)
- Referenzwechsel (1)
- Rehabilitation (1)
- Rejection (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Research Data Management (1)
- Research Infrastructure (1)
- Retinal diseases (1)
- Revolution <1848> (1)
- Rhabdomyoma (1)
- SENP (1)
- SMALL INTERFERING RNA (1)
- STRUCTURAL BASIS (1)
- SUMO (1)
- Salivary gland carcinoma (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Schweiz (1)
- Seizure (1)
- Semantics (1)
- Single muons (1)
- Small molecules (1)
- Spine density (1)
- Sprachtypologie (1)
- Swimming behavior (1)
- Synaptic plasticity (1)
- Syrien (1)
- Systematic Uncertainty (1)
- TEPT (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- Taliban (1)
- Taxonomy (1)
- Technical data (1)
- Terapia Dialéctica Conductual (1)
- Tetrahydro-Aldosteron (1)
- Therapeutics (1)
- Time Projection Chamber (1)
- Transverse Momentum (1)
- Transverse momentum (1)
- Trastorno de estrés postraumático (1)
- Triple negative (1)
- Type 2 diabetes (1)
- Venetoclax (1)
- Venous thromboembolism (1)
- Vesicles (1)
- Viral infection (1)
- Wide rapidity coverage (1)
- Yellow fluorescent protein (1)
- adrenal adenomas (1)
- anaemia (1)
- anterior chamber depth changes (1)
- antibiotic therapy (1)
- antibodies (1)
- apex (1)
- ascites (1)
- autoantibodies (1)
- b-cell lymphomas (1)
- bendamustine (1)
- biopsy (1)
- cardiac I/R injury (1)
- cataract surgery (1)
- cetuximab (1)
- charge-cluster glass (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- collagen degradation marker (1)
- combined modality therapy (1)
- dentate gyrus (1)
- diabetic macular edema (1)
- dislocation (1)
- double immune checkpoint inhibition (1)
- e-scooter (1)
- effective lens position (1)
- elderly patients (1)
- electric scooter (1)
- fear conditioning (1)
- fluctuation spectroscopy (1)
- fluocinolone acetonide (1)
- fracture (1)
- functional outcome (1)
- glass-like structural ordering (1)
- head and neck neoplasms (1)
- hematopoietic stem cell transplantation (1)
- imaging (1)
- immunoprecipitation (1)
- immunostaining (1)
- immunotherapy (1)
- in situ hybridization (1)
- induction therapy (1)
- lapatinib (1)
- laser microdissection (1)
- learning (1)
- leukapheresis (1)
- liver cirrhosis (1)
- lymphoma (1)
- mTOR inhibitor (1)
- mass spectrometry (1)
- medial prefrontal cortex (mPFC) (1)
- membranous urethra (1)
- memory consolidation and extinction (1)
- microdosing (1)
- mid-term urinary continence (1)
- molecular dynamics simulation (1)
- multidrug resistance (1)
- neoadjuvant therapy (1)
- neutralizing antibodies (1)
- organ preservation (1)
- organic charge-transfer salts (1)
- papilloma (1)
- percolation (1)
- primary aldosteronism (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (PID) (1)
- primärer Hyperaldosteronismus (1)
- prostate cancer (1)
- proteomics (1)
- pseudoexfoliative syndrome (1)
- radical prostatectomy (1)
- re-irradiation (1)
- registry for primary immunodeficiency (1)
- rituximab (1)
- screening routine (1)
- second line therapy (1)
- spectra (1)
- spike protein (1)
- surgery (1)
- tetrahydroaldosterone (1)
- traffic accident (1)
- transcranial magnetic stimulation (TMS) (1)
- transportation (1)
- trastuzumab (1)
- traumatic brain injury (1)
- treatment response (1)
- ursodeoxycholic acid (1)
- variants of concern (1)
- western blotting (1)
- √sN N = 2.76 TeV (1)
- 创伤后应激障碍 (1)
- 治疗依从性 (1)
- 治疗完整性 (1)
- 辩证行为疗法 (1)
Institute
- Physik (114)
- Frankfurt Institute for Advanced Studies (FIAS) (100)
- Informatik (99)
- Medizin (76)
- Geowissenschaften (7)
- Biowissenschaften (5)
- Biochemie und Chemie (4)
- Psychologie (3)
- Senckenbergische Naturforschende Gesellschaft (3)
- ELEMENTS (2)
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML.
TRIAL DESIGN: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size.
PATIENTS AND METHODS: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of <20,000/µl at the time of study entry and adequate organ function were eligible. Patients were randomised to receive azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary endpoint.
RESULTS: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival 215 days after a median follow up of 616 days.
CONCLUSIONS: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently halted due to an increased cardiac toxicity observed in the experimental arm.
Background: Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGIF is associated with BC bone metastasis or patient outcome and thus of potential interest. Methods: TGIF expression was analyzed by immunohistochemistry in 1197 formalin-fixed, paraffin-embedded tissue samples from BC patients treated in the GAIN (German Adjuvant Intergroup Node-Positive) study with two adjuvant dose-dense schedules of chemotherapy with or without bisphosphonate ibandronate. TGIF expression was categorized into negative/low and moderate/strong staining. Endpoints were disease-free survival (DFS), overall survival (OS) and time to primary bone metastasis as first site of relapse (TTPBM). Results: We found associations of higher TGIF protein expression with smaller tumor size (p= 0.015), well differentiated phenotype (p< 0.001) and estrogen receptor (ER)-positive BC (p< 0.001). Patients with higher TGIF expression levels showed a significantly longer disease-free (DFS: HR 0.75 [95%CI 0.59–0.95], log-rank p=0.019) and overall survival (OS: HR 0.69 [95%CI 0.50–0.94], log-rank p= 0.019), but no association with TTPBM (HR 0.77 [95%CI 0.51–1.16]; p= 0.213). Univariate analysis in molecular subgroups emphasized that elevated TGIF expression was prognostic for both DFS and OS in ER-positive BC patients (DFS: HR 0.68 [95%CI 0.51–0.91]; log-rank p= 0.009, interaction p= 0.130; OS: HR 0.60 [95%CI 0.41–0.88], log-rank p= 0.008, interaction p= 0.107) and in the HER2-negative subgroup (DFS:HR 0.67 [95%CI 0.50–0.88], log-rank p= 0.004, interaction p= 0.034; OS: HR 0.57 [95%CI 0.40–0.81], log-rank p= 0.002, interaction p= 0.015). Conclusions: Our results suggest that moderate to high TGIF expression is a common feature of breast cancer cells and that this is not associated with bone metastases as first site of relapse. However, a reduced expression is linked to tumor progression, especially in HER2-negative breast cancer.
Following publication of the original article, the authors noticed an incorrect affiliation for Christine Stürken and Udo Schumacher. The correct affiliations are as follows: Christine Stürken: Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Udo Schumacher: Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. The affiliations have been correctly published in this correction and the original article has been updated.
Background: Chronic congestive heart failure (CHF) is a complex disease with rising prevalence, compromised quality of life (QoL), unplanned hospital admissions, high mortality and therefore high burden of illness. The delivery of care for these patients has been criticized and new strategies addressing crucial domains of care have been shown to be effective on patients' health outcomes, although these trials were conducted in secondary care or in highly organised Health Maintenance Organisations. It remains unclear whether a comprehensive primary care-based case management for the treating general practitioner (GP) can improve patients' QoL. Methods/Design: HICMan is a randomised controlled trial with patients as the unit of randomisation. Aim is to evaluate a structured, standardized and comprehensive complex intervention for patients with CHF in a 12-months follow-up trial. Patients from intervention group receive specific patient leaflets and documentation booklets as well as regular monitoring and screening by a prior trained practice nurse, who gives feedback to the GP upon urgency. Monitoring and screening address aspects of disease-specific selfmanagement, (non)pharmacological adherence and psychosomatic and geriatric comorbidity. GPs are invited to provide a tailored structured counselling 4 times during the trial and receive an additional feedback on pharmacotherapy relevant to prognosis (data of baseline documentation). Patients from control group receive usual care by their GPs, who were introduced to guidelineoriented management and a tailored health counselling concept. Main outcome measurement for patients' QoL is the scale physical functioning of the SF-36 health questionnaire in a 12-month follow-up. Secondary outcomes are the disease specific QoL measured by the Kansas City Cardiomyopathy questionnaire (KCCQ), depression and anxiety disorders (PHQ-9, GAD-7), adherence (EHFScBS and SANA), quality of care measured by an adapted version of the Patient Chronic Illness Assessment of Care questionnaire (PACIC) and NTproBNP. In addition, comprehensive clinical data are collected about health status, comorbidity, medication and health care utilisation. Discussion: As the targeted patient group is mostly cared for and treated by GPs, a comprehensive primary care-based guideline implementation including somatic, psychosomatic and organisational aspects of the delivery of care (HICMAn) is a promising intervention applying proven strategies for optimal care. Trial registration: Current Controlled Trials ISRCTN30822978.
Major mood disorders, which primarily include bipolar disorder and major depressive disorder, are the leading cause of disability worldwide and pose a major challenge in identifying robust risk genes. Here, we present data from independent large-scale clinical data sets (including 29 557 cases and 32 056 controls) revealing brain expressed protocadherin 17 (PCDH17) as a susceptibility gene for major mood disorders. Single-nucleotide polymorphisms (SNPs) spanning the PCDH17 region are significantly associated with major mood disorders; subjects carrying the risk allele showed impaired cognitive abilities, increased vulnerable personality features, decreased amygdala volume and altered amygdala function as compared with non-carriers. The risk allele predicted higher transcriptional levels of PCDH17 mRNA in postmortem brain samples, which is consistent with increased gene expression in patients with bipolar disorder compared with healthy subjects. Further, overexpression of PCDH17 in primary cortical neurons revealed significantly decreased spine density and abnormal dendritic morphology compared with control groups, which again is consistent with the clinical observations of reduced numbers of dendritic spines in the brains of patients with major mood disorders. Given that synaptic spines are dynamic structures which regulate neuronal plasticity and have crucial roles in myriad brain functions, this study reveals a potential underlying biological mechanism of a novel risk gene for major mood disorders involved in synaptic function and related intermediate phenotypes.
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Methodology/Principal Findings: Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D3 (25[OH]D3) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061–2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D3<20 ng/mL) during all seasons, but 25(OH)D3 serum levels were not associated with treatment outcome.
Conclusions/Significance: Our study suggests a role of bioactive vitamin D (1,25[OH]2D3, calcitriol) in the response to treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D3 is not a suitable predictor of treatment outcome.
Background: Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
Methodology/Principal Findings: Associations between CYP2R1, GC, and DHCR7 genotypes that are determinants of reduced 25-hydroxyvitamin D (25[OH]D3) serum levels and the risk of HCV-related HCC development were investigated for 1279 chronic hepatitis C patients with HCC and 4325 without HCC, respectively. The well-known associations between CYP2R1 (rs1993116, rs10741657), GC (rs2282679), and DHCR7 (rs7944926, rs12785878) genotypes and 25(OH)D3 serum levels were also apparent in patients with chronic hepatitis C. The same genotypes of these single nucleotide polymorphisms (SNPs) that are associated with reduced 25(OH)D3 serum levels were found to be associated with HCV-related HCC (P = 0.07 [OR = 1.13, 95% CI = 0.99–1.28] for CYP2R1, P = 0.007 [OR = 1.56, 95% CI = 1.12–2.15] for GC, P = 0.003 [OR = 1.42, 95% CI = 1.13–1.78] for DHCR7; ORs for risk genotypes). In contrast, no association between these genetic variations and liver fibrosis progression rate (P>0.2 for each SNP) or outcome of standard therapy with pegylated interferon-α and ribavirin (P>0.2 for each SNP) was observed, suggesting a specific influence of the genetic determinants of 25(OH)D3 serum levels on hepatocarcinogenesis.
Conclusions/Significance: Our data suggest a relatively weak but functionally relevant role for vitamin D in the prevention of HCV-related hepatocarcinogenesis.
Rezensionen [2019]
(2019)
Verzeichnis
Einzelrezensionen
163 Babenhauserheide, Melanie: Harry Potter und die Widersprüche der Kulturindustrie. Eine ideologiekritische Analyse (DAVID N. SCHMIDT)
165 Ballis, Anja/Pecher, Claudia Maria/ Schuler, Rebecca (Hrsg.): Mehrsprachige Kinder- und Jugendliteratur. Überlegungen zur Systematik, Didaktik und Verbreitung (SVETLANA VISHEK)
167 Bannasch, Bettina/Matthes, Eva (Hrsg.): Kinder- und Jugendliteratur. Historische, erzähl- und medientheoretische, pädagogische und therapeutische Perspektiven (susanne blumesberger)
169 Batzke, Ina/ Erbacher, Eric C. /Heß, Linda M. / Lenhardt, Corinna (Hrsg.): Exploring the Fantastic. Genre, Ideology, and Popular Culture (THOMAS BITTERLICH)
170 Bertling, Maria: All-Age-Literatur. Die Entdeckung einer neuen Zielgruppe und ihrer Rezeptionsmodalitäten (NICOLA KÖNIG)
172 Blümer, Agnes: Mehrdeutigkeit übersetzen. Englische und französische Kinderliteraturklassiker der Nachkriegszeit in deutscher Übertrag (MARTINA SEIFERT)
174 Blumesberger, Susanne/Thunecke, Jörg (Hrsg.): Deutschsprachige Kinder- und Jugendliteratur während der Zwischenkriegszeit und im Exil. Schwerpunkt Österreich (KURT FRANZ)
176 Busch, Nathanael /Velten, Hans Rudolf (Hrsg.): Die Literatur des Mittelalters im Fantasyroman (SONJA LOIDL)
178 Cave, Roderick/Ayad, Sara (Hrsg.): Die Geschichte des Kinderbuches in 100 Büchern (ERNST SEIBERT)
180 Dettmar, Ute/Pecher, Claudia Maria/Schlesinger, Ron (Hrsg.): Märchen im Medienwechsel. Zur Geschichte und Gegenwart des Märchenfilms (MICHAEL STIERSTORFER)
182 Dommermuth, Clarissa: Wir sind dagegen – denn ihr seid dafür. Zur Tradition literarischer Jugendbewegungen im deutschsprachigen Raum (SUSANNE BLUMESBERGER)
184 Ellerbach, Benoît: L’Arabie contée aux Allemands. Fictions interculturelles chez Rafik Schami (ANNETTE KLIEWER)
185 Enklaar, Jattie/ Ester, Hans /Tax, Evelyne (Hrsg.): Studien über Kinder- und Jugendliteratur im europäischen Austausch von 1800 bis heute (IRIS SCHÄFER)
187 Ewers, Hans-Heino: Michael Ende neu entdecken. Was »Jim Knopf«,»Momo« und »Die unendliche Geschichte« Erwachsenen zu sagen haben (MARKUS JANKA)
189 Flegel, Monica/Parkes, Christopher (Hrsg.): Cruel Children in Popular Texts and Cultures (LENA HOFFMANN)
191 Garbe, Christine/Gürth, Christina et al. (Hrsg.): Attraktive Lesestoffe (nicht nur) für Jungen. Erzählmuster und Beispielanalysen zu populärer Kinder- und Jugendliteratur (THOMAS BITTERLICH)
193 Goga, Nina/Kümmerling-Meibauer, Bettina (Hrsg.): Maps and Mapping in Children’s Literature. Landscapes, Seascapes, and Cityscapes (Wolfgang Biesterfeld)
195 Hamer, Naomi /Nodelman, Perry / Reimer, Mavis (Hrsg.): More Words about Pictures. Current Research on Picturebooks and Visual/Verbal Texts for Young People (FARRIBA SCHULZ)
196 Hoffmann, Lena: Crossover. Mehrfachadressierung in Text, Markt und Diskurs (HEIDI LEXE)
198 Josting, Petra/Reuter, Frank/Roeder, Caroline/Wolters, Ute (Hrsg.): »Denn sie rauben sehr geschwind jedes böse Gassenkind.« ›Zigeuner‹-Bilder in Kinder- und Jugendmedien (KURT FRANZ)
200 Langemeyer, Peter /Knutsen, Karen Patrick (Hrsg.): Narratology Plus. Studies in Recent International Narratives for Children and
Young Adults / Narratologie Plus. Studien zur Erzählweise in aktueller internationaler Kinder- und Jugendliteratur (NADINE BIEKER)
202 Museumsinsel Lüttenheid (Hrsg.): Rudolf Dirks. Zwei Lausbuben und die Erfindung des modernen Comics (LUKAS SARVARI)
204 Oeste, Bettina/Preußer, Ulrike (Hrsg.): Neuvermessung deutschsprachiger Erinnerungsstrategien in der Kinder- und Jugendliteratur nach 1990 (annette kliewer)
206 Planka, Sabine (Hrsg.): Berlin. Bilder einer Metropole in erzählenden Medien für Kinder und Jugendliche (KATHARINA EGERER)
208 Press, Alexander: Die Bilder des Comics. Funktionsweisen aus kunst- und bildwissenschaftlicher Perspektive (RALF VOLLBRECHT)
209 Schenk, Klaus /Zeisberg, Ingold (Hrsg.): Fremde Räume. Interkulturalität und Semiotik des Phantastischen (ANNETTE KLIEWER)
211 Schweizerisches Institut für Kinder- und Jugendmedien SIKJM (Hrsg.): Atlas der Schweizer Kinderliteratur. Expeditionen und
Panoramen (SUSANNE RIEGLER)
Sammelrezensionen
213 Heinemann, Caroline: Produktionsräume im zeitgenössischen Kinder- und Jugendtheater. – Hentschel, Ingrid: Theater zwischen Ich und Welt. Beiträge zur Ästhetik des Kinder- und Jugendtheaters. Theorien – Praxis – Geschichte (PHILIPP SCHMERHEIM)
215 Janka, Marcus /Stierstorfer, Michael (Hrsg.): Verjüngte Antike. Griechisch-römische Mythologie in zeitgenössischen Kinder- und Jugendmedien. – Stierstorfer, Michael: Antike Mythologie in der Kinder- und Jugendliteratur der Gegenwart. Unsterbliche Götter- und Heldengeschichten? (KARINA BECKER)
218 Josting, Petra/Kruse, Iris (Hrsg.): Paul Maar. Bielefelder Poet in Residence 2015 | Paderborner Kinderliteraturtage 2016. – Wicke, Andreas /Roßbach, Nikola (Hrsg.): Paul Maar. Studien zum kinder- und jugendliterarischen Werk (SONJA MÜLLER-CARSTENS)
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR–ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 106, 1.08±0.11 × 105, 1.03±0.10 × 104, 1.02±0.09 × 103, 1.04±0.10 × 102 and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR–ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR–ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).
Stimulation of renal collecting duct principal cells with antidiuretic hormone (arginine-vasopressin, AVP) results in inhibition of the small GTPase RhoA and the enrichment of the water channel aquaporin-2 (AQP2) in the plasma membrane. The membrane insertion facilitates water reabsorption from primary urine and fine-tuning of body water homeostasis. Rho guanine nucleotide exchange factors (GEFs) interact with RhoA, catalyze the exchange of GDP for GTP and thereby activate the GTPase. However, GEFs involved in the control of AQP2 in renal principal cells are unknown. The A-kinase anchoring protein, AKAP-Lbc, possesses GEF activity, specifically activates RhoA, and is expressed in primary renal inner medullary collecting duct principal (IMCD) cells. Through screening of 18,431 small molecules and synthesis of a focused library around one of the hits, we identified an inhibitor of the interaction of AKAP-Lbc and RhoA. This molecule, Scaff10-8, bound to RhoA, inhibited the AKAP-Lbc-mediated RhoA activation but did not interfere with RhoA activation through other GEFs or activities of other members of the Rho family of small GTPases, Rac1 and Cdc42. Scaff10-8 promoted the redistribution of AQP2 from intracellular vesicles to the periphery of IMCD cells. Thus, our data demonstrate an involvement of AKAP-Lbc-mediated RhoA activation in the control of AQP2 trafficking.